Richard Bax, MBBS, MRCGP, FRCP Lon, FRCP Edin, FFPM, FIDSA

Senior Partner

Email: richard.bax@transcrip-partners.com

Richard is a Pharmaceutical Physician with over 32 years of industry experience, including working for Glaxo, Hoechst-Roussel, Lilly and ICI (now Astra Zeneca). He was VP at SmithKline Beecham from 1991-1999, working in London and Philadelphia, in charge of Global Anti-infective Clinical Development, resulting in over 15 successful NDAs /MAAs and launches including Famvir/penciclovir, Bactroban and Augmentin BD. Between 2000 and 2003, Richard was Chief Scientist to Biosyn, a microbicide company based in Philadelphia. He subsequently joined Chiron as VP and Clinical Director Europe. He was involved in the set-up of the EU part of the company and the successful MAA of Cubicin. He left 2.5 years later when Novartis absorbed Chiron. In May 2007 he joined Viropharma as VP Clinical Director Europe and was involved in the set up of the EU company and the EU transplant maribivir phase 3 studies.

Richard has been a pharmaceutical consultant to such companies as Bayer (Germany), British Biotech (UK), LG Pharma (Korea), Pantheco (Denmark), Quorex (US), Elitra (US), and Merlion (Singapore) and was also a member of their respective antibiotic advisory boards.

He was also a member of various working parties of the BSAC,ESCMID, European Union Grant Committee, EFPIA, IFPMA, Wellcome Trust, Surgical Infection Society (US) and the working party of the WHO on Bacterial Resistance as well as a consultant to the office of AIDS Research NIH US.

Richard is a non-executive director of Helperby, a spin out company from St Georges Hospital Medical School, London.

Richard has over 100 publications in peer reviewed journals including the BMJ, The Lancet, New England Journal of Medicine, Nature Medicine and Nature New Drugs on clinical trials, antibiotic resistance and prescribing, PK/PD predictors of outcome and the Pharmaceutical Industry.